1. Why the Patent Portfolio Is the Real Balance Sheet A company’s income statement tells you what it earned last […]
Drug Patent Alpha: How Pharma IP Data Predicts Stock Performance Before the Market Does Read Post »
Section 1: The Hatch-Waxman Architecture: Why Conflict Is a Feature, Not a Bug Most people who cover pharmaceutical equities understand
Generic drug development has a public relations problem. The phrase ‘generic drug’ suggests a simple act of copying, the pharmaceutical
Every blockbuster drug runs on a clock it cannot stop. The question is whether your legal and portfolio teams know
Section 1: Executive Summary and Key Takeaways Drug development is a decade-plus, multi-billion-dollar bet made in almost complete informational darkness.
How to read the exclusivity stack, predict loss-of-exclusivity dates, and turn patent data into budget certainty Why Patent Blindness Is
The generic pharmaceutical industry runs on a contradiction. It is one of the most consequential public health interventions of the
Section 1: Why Your Patent Portfolio IS Your Balance Sheet A widespread assumption among early-stage biotech founders is that patents
Section 1: The Patent Bargain and the 20-Year Illusion The Foundational Quid Pro Quo The pharmaceutical patent system rests on
Sign in or create a free account to read this DrugPatentWatch article
